Author’s response to reviews

Title: Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

Authors:

Lin Shen (melanie.blanchard@meditechmedia.com; linshenpku@163.com)
Ruihua Xu (xurh@sysucc.org.cn)
Xianjun Yu (yuxianjun@fudanpci.org)
Juhui Hao (jihuihao@yahoo.com)
Liwei Wang (syzlkgcp@163.com)
Hongming Pan (shonco@sina.cn)
Guohong Han (hangh@fmmu.edu.cn)
Jianming Xu (jmxu2003@yahoo.com)
Yanqiao Zhang (yanqiaozhang@126.com)
Shujun Yang (nkyang@126.com)
Jia Chen (chenjia@medmail.com.cn)
Jieer Ying (jieerying@aliyun.com)
Guanghai Dai (daigh2014@163.com)
Mingyu Li (mli@celgene.com)
Damir Begic (dbegic@celgene.com)
Brian Lu (blu@celgene.com)

Version: 1 Date: 02 Sep 2016

Author’s response to reviews:

1- Please provide separate email addresses for authors RX, XY, JH, LW, HP, GH, JX, YZ, SW, HC, JY, GD, ML, and DB on the title page; please use institutional email addresses if possible.
Email addresses were added to the title page

2- Please add a clear statement that nab-paclitaxel (Abraxane) is manufactured and sold in the US by Celgene Corporation, which funded the study and medical writing assistance as well as employing three authors (ML, DB, and BL, who also have stock ownership in Celgene Corporation).

Added to the Declarations section (lines 327 to 330)

3- Please add that Celgene Corporation employed three authors and funded medical writing assistance, as well as funding the study itself.

Amended Funding section (lines 354 to 356)

4- Please indicate in the manuscript ethics statement the actual name of the committee that approved the study. Please also indicate the form of consent (written or verbal) that was obtained from the patients (and an explanation if verbal consent was obtained instead of written).

Updated Ethics Approval section (lines 338 to 343)

5- Please add the date of registration to the manuscript.

Added next to trial registration number on line 74.